GSK Entered into an Exclusive Licence Agreement and SCYNEXIS to Develop and Commercialise Brexafemme (ibrexafungerp) for Fungal Infection

Shots:

SCYNEXIS to receive $90M up front, $503M in milestones incl. ~$70M in regulatory approval milestones, ~$115M in commercial milestones based on first commercial sale in invasive candidiasis (US/EU); ~$242.5M in sales milestones incl. $77.5M to be paid upon achievement of multiple thresholds up through $200M; $65M upon multiple thresholds b/w $300M & $500M & $50M at each threshold of $750M & $1B along with royalties across all indications
SCYNEXIS will also receive ~$75.5M in success-based development milestones & holds rights to all other assets derived from enfumafungin along with leading the execution & costs of the ongoing clinical studies of ibrexafungerp. GSK gets the first rights to negotiate for future compounds developed by Scynexis
GSK will get an exclusive license to develop, manufacture & commercialize ibrexafungerp & Brexafemme for all indications in all countries excl. greater China region & certain other countries already out-licensed by SCYNEXIS to third parties

Ref: GSK | Image: GSK

Related News:- SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis